BridgeBio Oncology director granted 31,675 stock options

BridgeBio Oncology Therapeutics director Frank McCormick received a new stock option grant.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics director Frank McCormick received a new stock option grant. He was awarded options for 31,675 shares of common stock at an exercise price of $7.73 per share. These options were granted at no upfront cost and are held as a direct ownership position.

The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date. Following this grant, his reported derivative holdings from this award total 31,675 underlying shares.

Insider Trade Summary

Grant/Award: 31,675 shares

Grant/Award 1 txn

Insider MCCORMICK FRANK

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,675	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,675 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

Option grant size: 31,675 shares Exercise price: $7.73 per share Total derivative shares after grant: 31,675 shares +1 more

4 metrics

Option grant size 31,675 shares Stock Option (Right to Buy) grant to director on 2026-06-16

Exercise price $7.73 per share Conversion or exercise price of the stock option

Total derivative shares after grant 31,675 shares Total shares following transaction for this option award

Option expiration 2036-06-15 Expiration date of the stock option grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 7.7300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares underlying the stock option vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Oncology Therapeutics (BBOT) report for Frank McCormick?

BridgeBio Oncology Therapeutics reported that director Frank McCormick received a stock option grant for 31,675 shares. The options relate to common stock and were awarded as compensation rather than an open-market purchase, reflecting routine equity-based director pay.

How many BridgeBio Oncology Therapeutics (BBOT) options were granted and at what price?

Frank McCormick was granted stock options covering 31,675 shares of BridgeBio Oncology Therapeutics common stock. The options have an exercise price of $7.73 per share, meaning he can buy shares at that price once the options vest, subject to the vesting conditions.

When do Frank McCormick’s BBOT stock options vest according to the Form 4?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Vesting is contingent on Frank McCormick’s continued service to BridgeBio Oncology Therapeutics through the applicable vesting date, as disclosed.

Is Frank McCormick’s BBOT option grant an open-market buy or a compensation award?

The transaction is a compensation-related award, not an open-market purchase. The Form 4 labels it as a grant or award acquisition with a transaction code A, covering 31,675 stock options granted at a $7.73 exercise price, issued at no upfront share purchase cost.

What is Frank McCormick’s reported position after this BBOT option grant?

After the grant, Frank McCormick’s reported derivative holdings from this award total 31,675 underlying shares. The Form 4 shows total shares following the transaction of 31,675 tied to this stock option, reflecting his newly granted but vesting-dependent equity exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCORMICK FRANK

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.73	06/16/2026		A		31,675		(1)	06/15/2036	Common Stock	31,675	$0	31,675	D

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)